Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations
- 5 March 2018
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 37 (5) , 1407-1411
Abstract
Adalimumab is a TNF-α blocker antibody similar in structure and function to natural human IgG1. Even if adalimumab is fully humanized, the development of anti-drug antibodies has been reported in several inflammatory conditions. The objective of our study was to assess the presence of anti-adalimumab antibodies (AAA) and their clinical relevance in a cohort of juvenile idiopathic arthritis (JIA) patients on adalimumab. This is a prospective observational cohort study recruiting JIA children. Experiments were performed using a validated surface plasmon resonance (SPR)-based optical assay (Biacore® T100). Disease activity was evaluated using the Juvenile Arthritis Disease Activity Score with 10 joint count (JADAS-10). The Mann–Whitney U test, Wilcoxon signed-rank test for paired samples, chi-square, and Fisher exact test were used to compare data. Pearson’s and Spearman’s correlation tests were used to determine correlation coefficients for entered variables: demographic, clinical, and serological data. Ten (37%) out of 27 patients included in the study had at least one AAA-positive sample. Patients developed AAA between 3 and 38 months after starting adalimumab. Seven (70%) out of 10 children with AAA positivity experienced at least a relapse compared to 4 (23.5%) out of 17 AAA-negative children (rs 0.45, p < 0.017). In conclusion, using an innovative and accurate assay method, we found a high incidence of anti-drug antibodies in a cohort of adalimumab-treated JIA patients observed over a mean period of 40 weeks; the presence of anti-adalimumab antibodies seemed to be related to the number of relapses.Keywords
This publication has 18 references indexed in Scilit:
- Higher order structures of Adalimumab, Infliximab and their complexes with TNFα revealed by electron microscopyProtein Science, 2017
- Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s diseaseJournal of Gastroenterology, 2013
- Immunogenicity to Therapeutic Proteins: Impact on PK/PD and EfficacyThe AAPS Journal, 2012
- Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity scoreArthritis & Rheumatism, 2012
- Development and validation of a composite disease activity score for juvenile idiopathic arthritisArthritis Care & Research, 2009
- Adalimumab with or without Methotrexate in Juvenile Rheumatoid ArthritisNew England Journal of Medicine, 2008
- Immunogenicity of anti-tumor necrosis factor antibodies—toward improved methods of anti-antibody measurementCurrent Opinion in Immunology, 2008
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Juvenile idiopathic arthritisThe Lancet, 2007
- International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.2004